other material
confidence high
sentiment positive
materiality 0.85
IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM
IN8BIO, INC.
- Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.
- Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.
- No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.
- Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025.